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Abstract: Early detection of precancerous cells in the cervix and their clinical management is the main purpose of cervical 
cancer prevention and treatment programs. Cytological ﬁ  ndings or testing for high risk (HR)-human papillomavirus (HPV) 
are inadequately sensitive for use in triage of women at high risk for cervical cancer. The current study is an exploratory 
study to identify candidate surface-enhanced laser desorption/ionization (SELDI) time of ﬂ  ight (TOF) mass spectrometry 
(MS) protein proﬁ  les in plasma that may distinguish cervical intraepithelial neoplasia (CIN 3) from CIN 1 among women 
infected with HR-HPV. We evaluated the SELDI-TOF-MS plasma protein proﬁ  les of HR-HPV positive 32 women with 
CIN 3 (cases) and 28 women with CIN1 (controls). Case-control status was kept blinded and triplicates of each sample and 
quality control plasma samples were randomized and after robotic sample preparations were run on WCX2 chips. After 
alignment of mass/charge (m-z values), an iterative method was used to develop a classiﬁ  er on a training data set that had 
28 cases and 22 controls. The classiﬁ  er developed was used to classify the subjects in a test data set that has six cases and 
six controls. The classiﬁ  er separated the cases from controls in the test set with 100% sensitivity and 100% speciﬁ  city sug-
gesting the possibility of using plasma SELDI protein proﬁ  les to identify women who are likely to have CIN 3 lesions.
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Introduction
Pap smear is the most commonly used diagnostic test used to identify women who are at risk of devel-
oping cervical cancer. An estimated 50 million Pap smears are performed each year in the United States 
(Walsh, 1998) and 6% of these are diagnosed as low-grade squamous intraepithelial lesions (LSILs) or 
as atypical squamous cells of undetermined signiﬁ  cance (ASCUS) (Paavonen et al. 1990). Although 
there is general consensus that cytologically diagnosed high-grade squamous intraepithelial lesions 
(HSILs) should be evaluated by colposcopy and biopsy, there has been no consensus as to the clinical 
management of women diagnosed with ASCUS or LSILs. Current options include immediate colpos-
copy and directed biopsy or follow-up with repeat cytology every 4–6 months and colposcopy with 
repeated abnormal cytology. The annual cost associated with these treatment options in the U.S.A. is 
estimated to be over one billion dollars (Schechter, 1996). Since HR-HPV is the main risk factor for 
cervical cancer, recent studies have investigated the use of HPV testing in the clinical management of 
these lesions. The ASCUS/LSIL Triage Study for cervical cancer (ALTS) conducted by the NCI demon-
strated that HPV testing is sensitive in detecting underlying precancerous lesions (CIN 2 or 3) among 
women with a Pap test diagnosis of ASCUS (Solomon et al. 2001), but HPV testing is not useful for 
women with a Pap test diagnosis of LSIL (ALTS investigators, 2000). Therefore, novel markers with 
higher speciﬁ  city for the presence of precancerous lesions among HR-HPV positive are needed and 
this will improve cervical cancer screening and reduce the cost associated with patient care. As discussed 
below, recent advancements in proteomic research have yielded techniques to aid in novel protein 
biomarker identiﬁ  cation.
Because the cause of most human diseases lies in the functional dysregulation of protein interactions, 
advances in proteomic technologies represent exciting ways to explore the disease processes at the 
molecular level. The identiﬁ  cation, quantiﬁ  cation, classiﬁ  cation and functional assignment of proteins Cancer Informatics 2006: 2 346
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are essential to the full understanding of these 
molecular events. Since mammalian systems are 
much more complex than can be deciphered by 
their genes alone, expression analysis directly at 
the protein level is thought to be necessary to 
unravel the critical changes that occur as part of 
pathogenesis of a disease (Srinivas et al. 2001).
The surface-enhanced laser desorption/ioniza-
tion (SELDI) time of ﬂ  ight (TOF) mass spectrom-
etry (MS) is one such technique with considerable 
potential for the detection and quantitation of 
protein in a wide variety of human tissue samples 
(Wright et al. 1999) and appear to be an important 
diagnostic tool for a whole range of diseases. 
Preliminary applications of proteomic techniques 
are published in the area of cervical cancer using 
two-dimensional gel analysis (Bae et al. 2005) and 
SELDI (Wong et al. 2004). These studies demon-
strate the ability of proteomics approach to distin-
guish cervical cancer from its normal counterpart. 
If this approach is also workable in the analysis of 
non invasive samples such as plasma, urine, exfo-
liated cervical cells or cervical mucous, it might 
potentially be used in the diagnosis of underlying 
precancerous cervical lesions in high-risk women. 
To our knowledge, there are no published reports 
demonstrating the usefulness of SELDI protein 
proﬁ  les to identify HR-HPV positive subjects who 
are likely to have underlying true precancerous 
lesions of the cervix.
The current study is an exploratory study to 
identify candidate SELDI-TOF MS protein 
proﬁ  les in plasma that may aid in distinguishing 
CIN 3 from CIN 1 among women positive for 
HR-HPV.
Materials and Methods
Samples
The plasma samples used were from a previously 
conducted study of cervical neoplasia (nutrition 
ancillary study of the ASCUS/LSIL Triage Study 
for cervical cancer (ALTS) where HPV status (as 
detected by the Hybrid Capture 2 assay-Digene 
Diagnostics) and cervical diagnoses were known 
(Piyathilake et al. 2004). Plasma samples from 
sixty HR-HPV positive women diagnosed with 
CIN 1 (n = 28) and CIN 3 (n = 32) were randomly 
selected from the prior study and were used in this 
study. A randomized template that was generated 
by the statistician and that included triplicate 
samples from each case (CIN 3) and control 
(CIN 1) plasma sample was developed to ensure 
samples were run randomly on the system. Case-
control status was kept blinded and the protein 
proﬁ  le data generated as described below was sent 
directly to the statistician for analysis.
Methods
The plasma samples were prepared in triplicate 
and diluted 1:10 in binding buffer (100mM Ammo-
nium Acetate pH 4.5, 0.1% Triton X-100) using 
the Biomek 2000 Robotics System (Beckman 
Coulter). The plasma samples (100 μl) were added 
to a pre-washed bioprocessor containing the 
WCX2, eight spot protein chips (Ciphergen 
Biosystem, Inc). The samples were incubated on 
a shaker for 2 hours at room temperature. The chips 
were washed twice with binding buffer and twice 
with HPLC grade H20. The bioprocessor was disas-
sembled and the chips were washed several times 
with HPLC grade H20. Each spot was allowed to 
air dry and 0.5 μl of sinapinic acid (energy 
absorbing molecule) was added twice to each spot. 
The chips were read on the Ciphergen Protein Chip 
Reader Series PBS II using the following param-
eters: Molecular Weight range–1000 to 15,000, High 
Mass–20,000, Intensity–180, and Sensitivity–7. 
Statistical Analysis
Pre-processing of data and creating 
training and test sets
The mean spectrum for an individual was obtained 
by averaging across the three replicate spectra for 
that individual. The m-z values for the CIN 3 group 
were slightly different from the CIN 1 group, but 
these differences were within the expected margin 
of error (0.2%) of the instrument. The average 
m-z values of both groups at each point were used 
as the estimated m-z value. The error of +/– 0.2% 
was used to develop a new variable index, which 
was the upper limit of the m-z interval within this 
error range. A total of 530 index variables were 
used to represent the 10,300 m-z values. Peaks 
were defined as the maximum intensity value 
within each set of m-z values represented by the 
new variable index. Each group had 530 peaks. 
The data sets were then randomly divided into Cancer Informatics 2006: 2  347
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training and test sets. Six patients from each group 
were randomly selected to create the test set. 
Therefore, the training set consisted of 28 CIN 3 
and 22 CIN 1.
Principal component analysis (PCA)
PCA plot which places the components in terms 
of the proportion of variance in the data that is 
attributable to the particular combination was used 
to visually demonstrate the differences in the 
groups before building a classiﬁ  er in order to assess 
the possibility of obtaining a good classiﬁ  er. The 
PCA components are orthogonal to each other. 
Therefore, the ﬁ  rst principal component accounts 
for the largest amount of variability and the second 
component accounts for the largest amount of 
variability unaccounted for by the first. The 
orthogonality of the components allows their repre-
sentation as axes in a two-dimensional plot. If the 
variability explained by the components is the 
variability associated with the differences in the 
two groups (CIN 3 and CIN 1), and not the random 
noise, the principal component plot will visually 
demonstrate the differences between the groups.
Building a classiﬁ  er
An iterative process was implemented to develop 
a classiﬁ  er. At each iteration, a random sample of 
18 CIN 1 and 22 CIN 3 was selected from the 
training data set. The peaks that were statistically 
signiﬁ  cantly different based on a Wilcoxon Rank 
Sum test were then subjected to a stepwise discrim-
inant analysis. This procedure produced a list of 
index values at which the intensities were most 
likely to separate the two groups. This list of 
possible discriminators was stored. The entire 
process was repeated 300 times in this preliminary 
analysis. Index values that occurred in at least 270 
of the 300 (90%) lists were selected to put into the 
classiﬁ  er. This error rate of the classiﬁ  er was esti-
mated by using the classiﬁ  er to classify the groups 
in the test data set. 
Results
The PCA was based on the entire set of 530 index 
values. The ﬁ  rst two components explained 37 
percent of the variability in the data. As shown 
in Figure 1, the PCA plot between CIN 3 and CIN 
using these ﬁ  rst two components suggested that 
it is possible to obtain a good separation between 
the groups. There were ﬁ  ve regions in the spectra 
that occurred in 90% of the lists produced by the 
stepwise discriminant procedure. These consisted 
of the region between m_z 2261–2282b (index 
28, 29), m_z 2371–2392 (index, 38), and m_z 
2426–2437 (index 43, 44). As shown in Figure 2, 
a subset of these ﬁ  ve m_z regions i.e. m_z 2426–
2437 groups provided 100% separation between 
the groups.
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Discussion
An important application of SELDI is the simul-
taneous analysis of multiple proteins to establish 
“ﬁ  ngerprint” proﬁ  les that discriminate disease 
from non-disease. This is an important approach 
since no single biomarker or protein by itself will 
improve the early detection/diagnosis of diseases 
including cancer or pre-cancer. Protein based 
approaches are utilized to study the natural history 
and treatment of several cancers including ovarian 
(Lin et al. 2006), breast (Wulfkuhle et al. 2001), 
colon/colorectal (Lawrie et al. 2001; Ward et al. 
2006; Engwegen et al. 2006) prostate (Waghray 
et al. 2001), head and neck (Roesch-Ely et al. 
2006), endometrial (Zhu et al. 2006), nasopharynx 
(Ho et al. 2006), bladder (Langbein et al. 2006), 
hepatocellular (Ward et al. 2006) and gastric cancer 
(Liang et al. 2006). Protein proﬁ  ling of body ﬂ  uids 
such as nipple aspirate ﬂ  uid (NAF) has shown to 
be rapid, reproducible, and capable of identifying 
protein signatures that appear to differentiate NAF 
samples from breast cancer patients and healthy 
controls, including those with an abnormal 
mammogram who were later proven to be biopsy 
normal (Paweletz et al. 2001). The use of SELDI 
protein proﬁ  les to detect putative breast cancer 
markers in peripheral samples such as saliva has 
also been reported in recent studies (Streckfus 
et al. 2006). A few studies have reported on the 
ability of serum protein proﬁ  les to separate benign 
hyperplasia from cancer and non-cancer tissues 
(Qu et al. 2002). Although in virology, much more 
limited use has been made of proteomics, use of 
several proteomic approaches for the analysis of 
HIV-cellular receptor interactions, the molecular 
mechanisms of transport of herpes simplex virus 
within neurons, and the structure of the tegument 
of herpes simplex virus is beginning to be appreci-
ated (Bernhard et al. 2005).
Our preliminary study demonstrated that plasma 
protein proﬁ  les are signiﬁ  cantly different between 
women diagnosed with CIN 1 and CIN 3. Biolog-
ically, it is plausible to see difference in protein 
profiles between HPV positive women who 
develop CIN 3 and HPV positive women who don’t 
develop CIN 3 because several biological pathways 
related to HPV (example: HPV integration which 
may result in development of CIN 3 lesions) could 
be different between HPV positive women who 
develop CIN 3 and who don’t. Cervical epithelial 
cells exposed to HPV which undergo transforma-
tion to pre-neoplastic lesions such as CIN 3 are 
very likely to differentially express signaling 
molecules responsible for host responses following 
HPV infection that resulted in CIN 3 and these 
molecules are likely to be present in the microen-
vironment of cervical cells and in the circulation. 
Identiﬁ  cation of such molecules will have enor-
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Figure 2. The region of the spectra of CIN 3 and CIN 1 groups that provided 100% separation between the groups.Cancer Informatics 2006: 2  349
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mous clinical applications. Triage of HPV positive 
women by protein biomarkers could yield enor-
mous cost savings and other important beneﬁ  ts 
include less invasive sample collection and incon-
venience regarding referral.
These results, however, have to be considered 
with caution. SELDI-TOF-MS analysis is a very 
sensitive method for determining differences in 
protein spectra of complex samples including 
plasma and serum. Because of this sensitivity, the 
method is very susceptible to the effects of various 
biases. Since cases of CIN 3 and of CIN 1 were 
selected randomly from participants from the ALTS 
Nutrition Ancillary Study, we know of no biases 
which separate the samples of CIN 3 from those 
of CIN 1. Similarly, because the triplicate aliquots 
of the samples were run randomly, there should be 
no bias in the analysis. Before ﬁ  nal conclusions 
can be drawn, however, it is necessary to further 
evaluate this classiﬁ  cation model by using an 
independent replication set, which will allow more 
precise conclusions about the accuracy of this clas-
sification. These pilot results also warrant an 
expanded study using SELDI-TOF-MS analysis 
to evaluate samples of plasma and other samples 
(cervical cells and cervical mucous) from patients 
with a wide range of cervical lesions to determine 
if these can be classiﬁ  ed successfully. A study is 
currently underway at the University of Alabama 
(U54 CA118948) to generate this data.
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